[1]
Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. JAMA. 1993 Sep 8:270(10):1217-21
[PubMed PMID: 8355384]
[2]
Hildebrandt T, Harty S, Langenbucher JW. Fitness supplements as a gateway substance for anabolic-androgenic steroid use. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors. 2012 Dec:26(4):955-62. doi: 10.1037/a0027877. Epub 2012 Apr 9
[PubMed PMID: 22486333]
[3]
Piacentino D, Kotzalidis GD, Del Casale A, Aromatario MR, Pomara C, Girardi P, Sani G. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Current neuropharmacology. 2015 Jan:13(1):101-21. doi: 10.2174/1570159X13666141210222725. Epub
[PubMed PMID: 26074746]
Level 1 (high-level) evidence
[4]
Lusetti M, Licata M, Silingardi E, Bonsignore A, Palmiere C. Appearance/Image- and Performance-Enhancing Drug Users: A Forensic Approach. The American journal of forensic medicine and pathology. 2018 Dec:39(4):325-329. doi: 10.1097/PAF.0000000000000424. Epub
[PubMed PMID: 30153114]
[5]
Jones IA, Togashi R, Hatch GFR 3rd, Weber AE, Vangsness CT Jr. Anabolic steroids and tendons: A review of their mechanical, structural, and biologic effects. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2018 Nov:36(11):2830-2841. doi: 10.1002/jor.24116. Epub 2018 Sep 5
[PubMed PMID: 30047601]
[6]
Armstrong JM, Avant RA, Charchenko CM, Westerman ME, Ziegelmann MJ, Miest TS, Trost LW. Impact of anabolic androgenic steroids on sexual function. Translational andrology and urology. 2018 Jun:7(3):483-489. doi: 10.21037/tau.2018.04.23. Epub
[PubMed PMID: 30050806]
[8]
Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Annals of epidemiology. 2014 May:24(5):383-98. doi: 10.1016/j.annepidem.2014.01.009. Epub 2014 Jan 30
[PubMed PMID: 24582699]
Level 1 (high-level) evidence
[9]
Cohen J, Collins R, Darkes J, Gwartney D. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. Journal of the International Society of Sports Nutrition. 2007 Oct 11:4():12. doi: 10.1186/1550-2783-4-12. Epub 2007 Oct 11
[PubMed PMID: 17931410]
[10]
Sjöqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet (London, England). 2008 May 31:371(9627):1872-82. doi: 10.1016/S0140-6736(08)60801-6. Epub
[PubMed PMID: 18514731]
[11]
de Ronde W, Smit DL. Anabolic androgenic steroid abuse in young males. Endocrine connections. 2020 Apr:9(4):R102-R111. doi: 10.1530/EC-19-0557. Epub
[PubMed PMID: 32229704]
[12]
Pope HG Jr, Kanayama G, Hudson JI. Risk factors for illicit anabolic-androgenic steroid use in male weightlifters: a cross-sectional cohort study. Biological psychiatry. 2012 Feb 1:71(3):254-61. doi: 10.1016/j.biopsych.2011.06.024. Epub 2011 Aug 12
[PubMed PMID: 21839424]
Level 2 (mid-level) evidence
[13]
Friedl KE, Dettori JR, Hannan CJ Jr, Patience TH, Plymate SR. Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. The Journal of steroid biochemistry and molecular biology. 1991:40(4-6):607-12
[PubMed PMID: 1958561]
[14]
McBride JA, Carson CC 3rd, Coward RM. The Availability and Acquisition of Illicit Anabolic Androgenic Steroids and Testosterone Preparations on the Internet. American journal of men's health. 2018 Sep:12(5):1352-1357. doi: 10.1177/1557988316648704. Epub 2016 May 11
[PubMed PMID: 27170675]
[15]
Fyksen TS, Vanberg P, Gjesdal K, von Lueder TG, Bjørnerheim R, Steine K, Atar D, Halvorsen S. Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes. Scandinavian journal of medicine & science in sports. 2022 Aug:32(8):1170-1181. doi: 10.1111/sms.14172. Epub 2022 May 4
[PubMed PMID: 35460300]
[16]
Hudson JI, Hudson Y, Kanyama G, Schnabel J, Javaras KN, Kaufman MJ, Pope HG Jr. Causal factors in childhood and adolescence leading to anabolic-androgenic steroid use: A machine learning approach. Drug and alcohol dependence reports. 2024 Mar:10():100215. doi: 10.1016/j.dadr.2023.100215. Epub 2023 Dec 29
[PubMed PMID: 38304122]
[17]
Smit DL, de Hon O, Venhuis BJ, den Heijer M, de Ronde W. Baseline characteristics of the HAARLEM study: 100 male amateur athletes using anabolic androgenic steroids. Scandinavian journal of medicine & science in sports. 2020 Mar:30(3):531-539. doi: 10.1111/sms.13592. Epub 2019 Nov 21
[PubMed PMID: 31663164]
[18]
Bulens A, Calzo JP, Eik-Nes TT, Beccia A, Raffoul A, Sarda V, Austin SB. Anabolic Steroid Initiation Among Boys and Young Men After Use of Muscle-Building Supplements. JAMA network open. 2024 Dec 2:7(12):e2450566. doi: 10.1001/jamanetworkopen.2024.50566. Epub 2024 Dec 2
[PubMed PMID: 39666340]
[19]
Eik-Nes TT, Austin SB, Blashill AJ, Murray SB, Calzo JP. Prospective health associations of drive for muscularity in young adult males. The International journal of eating disorders. 2018 Oct:51(10):1185-1193. doi: 10.1002/eat.22943. Epub 2018 Sep 10
[PubMed PMID: 30260492]
[20]
Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings. JAMA network open. 2018 Oct 5:1(6):e183337. doi: 10.1001/jamanetworkopen.2018.3337. Epub 2018 Oct 5
[PubMed PMID: 30646238]
[21]
Cohen PA, Avula B, Katragunta K, Travis JC, Khan I. Presence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements. JAMA network open. 2023 Jul 3:6(7):e2323879. doi: 10.1001/jamanetworkopen.2023.23879. Epub 2023 Jul 3
[PubMed PMID: 37459101]
[22]
Wenbo Z, Yan Z. The Uses of Anabolic Androgenic Steroids Among Athletes; Its Positive and Negative Aspects- A Literature Review. Journal of multidisciplinary healthcare. 2023:16():4293-4305. doi: 10.2147/JMDH.S439384. Epub 2023 Dec 29
[PubMed PMID: 38170017]
[23]
Bulut Y, Rasmussen JJ, Brandt-Jacobsen N, Frystyk J, Thevis M, Schou M, Gustafsson F, Hasbak P, Kistorp C. Coronary Microvascular Dysfunction Years After Cessation of Anabolic Androgenic Steroid Use. JAMA network open. 2024 Dec 2:7(12):e2451013. doi: 10.1001/jamanetworkopen.2024.51013. Epub 2024 Dec 2
[PubMed PMID: 39680410]
[25]
Windfeld-Mathiasen J, Horwitz H, Biering-Sørensen T, Olsen FJ. Anabolic steroids and cardiovascular morbidity. Ugeskrift for laeger. 2024 Oct 14:186(42):. pii: V04240260. doi: 10.61409/V04240260. Epub
[PubMed PMID: 39531029]
[26]
Kaufman MJ, Kanayama G, Hudson JI, Pope HG Jr. Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia? Neuroscience and biobehavioral reviews. 2019 May:100():180-207. doi: 10.1016/j.neubiorev.2019.02.014. Epub 2019 Feb 25
[PubMed PMID: 30817935]
[27]
Iacovino JR. Non-Physiologic Doses of Androgenic Anabolic Steroids: Mortality and Underwriting Assessment. Journal of insurance medicine (New York, N.Y.). 2024 Nov 1:51(3):171-174. doi: 10.1029/AAIMEDICINE-D-24-00028.1. Epub
[PubMed PMID: 39586065]
[28]
Nolan T. Mortality of anabolic steroids users and other research. BMJ (Clinical research ed.). 2024 Mar 21:384():q680. doi: 10.1136/bmj.q680. Epub 2024 Mar 21
[PubMed PMID: 38514077]
[29]
Pärssinen M, Kujala U, Vartiainen E, Sarna S, Seppälä T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. International journal of sports medicine. 2000 Apr:21(3):225-7
[PubMed PMID: 10834358]
[30]
Fabresse N, Grassin-Delyle S, Etting I, Alvarez JC. Detection and quantification of 12 anabolic steroids and analogs in human whole blood and 20 in hair using LC-HRMS/MS: application to real cases. International journal of legal medicine. 2017 Jul:131(4):989-999. doi: 10.1007/s00414-017-1552-3. Epub 2017 Feb 24
[PubMed PMID: 28236045]
Level 3 (low-level) evidence
[31]
So YM, Kwok WH, Ching CCW, Wong COL, Wan TSM, Ho ENM. Detection of Over 110 Anabolic-Androgenic Steroids, Corticosteroids and/or Their Esters in Horse Hair Using Ultra-High-Performance Liquid Chromatography-High-Resolution Mass Spectrometry and Gas Chromatography-Tandem Mass Spectrometry After Solid-Supported Liquid Extraction. Drug testing and analysis. 2024 Dec 10:():. doi: 10.1002/dta.3837. Epub 2024 Dec 10
[PubMed PMID: 39655796]
[32]
Ji Z, Liao L, Ge Y, Liu M, Fang X, Sun H, Zheng S, Deng X. Screening anabolic androgenic steroids in human urine: an application of the state-of-the-art gas chromatography-Orbitrap high-resolution mass spectrometry. Analytical and bioanalytical chemistry. 2024 May:416(13):3223-3237. doi: 10.1007/s00216-024-05272-2. Epub 2024 Apr 4
[PubMed PMID: 38573345]
[33]
Bohlin KP, Pohanka A, Andersson A, Villén T, Ekström L. Detection of anabolic agents including selective androgen receptor modulators in samples outside of sport. Drug testing and analysis. 2024 Aug:16(8):827-834. doi: 10.1002/dta.3600. Epub 2023 Nov 20
[PubMed PMID: 37986708]
[35]
Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: How do they work and what are the risks? Frontiers in endocrinology. 2022:13():1059473. doi: 10.3389/fendo.2022.1059473. Epub 2022 Dec 19
[PubMed PMID: 36644692]
[36]
Melo Junior AF, Dalpiaz PLM, Sousa GJ, Oliveira PWC, Birocale AM, Andrade TU, Abreu GR, Bissoli NS. Nandrolone alter left ventricular contractility and promotes remodelling involving calcium-handling proteins and renin-angiotensin system in male SHR. Life sciences. 2018 Sep 1:208():239-245. doi: 10.1016/j.lfs.2018.07.041. Epub 2018 Jul 21
[PubMed PMID: 30040952]
[37]
Zhou S, Glowacki J. Dehydroepiandrosterone and Bone. Vitamins and hormones. 2018:108():251-271. doi: 10.1016/bs.vh.2018.01.005. Epub 2018 Feb 24
[PubMed PMID: 30029729]
[38]
Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. British journal of pharmacology. 2008 Jun:154(3):522-8. doi: 10.1038/bjp.2008.118. Epub 2008 Apr 14
[PubMed PMID: 18414389]
[39]
Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003 Nov:144(11):5081-8
[PubMed PMID: 12960001]
[42]
Goldstein I, Chidambaram N, Dobs A, King S, Miner M, Ramasamy R, Yafi FA, Khera M. Newer formulations of oral testosterone undecanoate: development and liver side effects. Sexual medicine reviews. 2025 Jan 31:13(1):33-40. doi: 10.1093/sxmrev/qeae062. Epub
[PubMed PMID: 39291780]
[43]
Miner M, Wang C, Kaminetsky J, Khera M, Goldstein I, Carson C 3rd, Chidambaram N, King S, Dobs A. Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology. 2024 Sep 10:():. doi: 10.1111/andr.13747. Epub 2024 Sep 10
[PubMed PMID: 39252657]
[44]
Bernstein JS, Dhingra OP. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Therapeutic advances in urology. 2024 Jan-Dec:16():17562872241241864. doi: 10.1177/17562872241241864. Epub 2024 Apr 10
[PubMed PMID: 38606384]
Level 3 (low-level) evidence
[45]
Mann A, Strange RC, König CS, Hackett G, Haider A, Haider KS, Desnerck P, Ramachandran S. Testosterone replacement therapy: association with mortality in high-risk patient subgroups. Andrology. 2024 Sep:12(6):1389-1397. doi: 10.1111/andr.13582. Epub 2023 Dec 26
[PubMed PMID: 38148671]
[46]
Campbell K, Muthigi A, Ghomeshi A, Schuppe K, Sandler MD, Ramasamy R. Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights. Drug, healthcare and patient safety. 2023:15():73-84. doi: 10.2147/DHPS.S383130. Epub 2023 Mar 31
[PubMed PMID: 37025099]
[47]
Solimini R, Rotolo MC, Mastrobattista L, Mortali C, Minutillo A, Pichini S, Pacifici R, Palmi I. Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. European review for medical and pharmacological sciences. 2017 Mar:21(1 Suppl):7-16
[PubMed PMID: 28379599]
[48]
Pope HG Jr, Kanayama G. Body Image Disorders and Anabolic Steroid Withdrawal Hypogonadism in Men. Endocrinology and metabolism clinics of North America. 2022 Mar:51(1):205-216. doi: 10.1016/j.ecl.2021.11.007. Epub 2022 Feb 8
[PubMed PMID: 35216717]
[49]
Grant B, Kean J, Vali N, Campbell J, Maden L, Bijral P, Dhillo WS, McVeigh J, Quinton R, Jayasena CN. The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men. Substance abuse treatment, prevention, and policy. 2023 Nov 11:18(1):66. doi: 10.1186/s13011-023-00573-8. Epub 2023 Nov 11
[PubMed PMID: 37951896]
Level 3 (low-level) evidence
[50]
Dunn M, Dawe J, Eu B, Lee K, Piatkowski T, Stoové M. The health effects of non-prescribed anabolic-androgenic steroid use: Findings from The Performance and image-enhancing drugs UseRS' Health (PUSH) audit. Drug and alcohol review. 2024 Nov:43(7):1967-1975. doi: 10.1111/dar.13899. Epub 2024 Jul 7
[PubMed PMID: 38973204]
[51]
Albano GD, Amico F, Cocimano G, Liberto A, Maglietta F, Esposito M, Rosi GL, Di Nunno N, Salerno M, Montana A. Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review. Healthcare (Basel, Switzerland). 2021 Jan 19:9(1):. doi: 10.3390/healthcare9010097. Epub 2021 Jan 19
[PubMed PMID: 33477800]
[52]
Azevedo RA, Gualano B, Teixeira TA, Nascimento BCG, Hallak J. Abusive use of anabolic androgenic steroids, male sexual dysfunction and infertility: an updated review. Frontiers in toxicology. 2024:6():1379272. doi: 10.3389/ftox.2024.1379272. Epub 2024 Apr 22
[PubMed PMID: 38711907]
[53]
Vorona E, Nieschlag E. Adverse effects of doping with anabolic androgenic steroids in competitive athletics, recreational sports and bodybuilding. Minerva endocrinologica. 2018 Dec:43(4):476-488. doi: 10.23736/S0391-1977.18.02810-9. Epub 2018 Feb 19
[PubMed PMID: 29463075]
[54]
Skrzypiec-Spring M, Rozmus J, Abu Faraj G, Brawańska-Maśluch K, Kujawa K, Szeląg A. Abuse of Anabolic-Androgenic Steroids as a Social Phenomenon and Medical Problem-Its Potential Negative Impact on Reproductive Health Based on 50 Years of Case Report Analysis. Journal of clinical medicine. 2024 Oct 2:13(19):. doi: 10.3390/jcm13195892. Epub 2024 Oct 2
[PubMed PMID: 39407952]
Level 3 (low-level) evidence
[55]
Grant B, Hyams E, Davies R, Minhas S, Jayasena CN. Androgen abuse: Risks and adverse effects in men. Annals of the New York Academy of Sciences. 2024 Aug:1538(1):56-70. doi: 10.1111/nyas.15187. Epub 2024 Jul 23
[PubMed PMID: 39041466]
[56]
Momoh R. Anabolic-Androgenic Steroid Abuse Causes Cardiac Dysfunction. American journal of men's health. 2024 Mar-Apr:18(2):15579883241249647. doi: 10.1177/15579883241249647. Epub
[PubMed PMID: 38686840]
[57]
Tungesvik HM, Bjørnebekk A, Hisdal J. Impaired vascular function among young users of anabolic-androgenic steroids. Scientific reports. 2024 Aug 19:14(1):19201. doi: 10.1038/s41598-024-70110-5. Epub 2024 Aug 19
[PubMed PMID: 39160232]
[58]
Grandperrin A, Schuster I, Rupp T, Izem O, Obert P, Nottin S. Left ventricular dyssynchrony and post-systolic shortening in young bodybuilders using anabolic-androgenic steroids. American journal of physiology. Heart and circulatory physiology. 2021 Sep 1:321(3):H509-H517. doi: 10.1152/ajpheart.00136.2021. Epub 2021 Jul 9
[PubMed PMID: 34242095]
[59]
Darke S, Torok M, Duflou J. Sudden or unnatural deaths involving anabolic-androgenic steroids. Journal of forensic sciences. 2014 Jul:59(4):1025-8. doi: 10.1111/1556-4029.12424. Epub 2014 Feb 19
[PubMed PMID: 24611438]
[60]
Abdullah R, Bjørnebekk A, Hauger LE, Hullstein IR, Edvardsen T, Haugaa KH, Almaas VM. Severe biventricular cardiomyopathy in both current and former long-term users of anabolic-androgenic steroids. European journal of preventive cardiology. 2024 Mar 27:31(5):599-608. doi: 10.1093/eurjpc/zwad362. Epub
[PubMed PMID: 37992194]
[61]
Thiblin I, Garmo H, Garle M, Holmberg L, Byberg L, Michaëlsson K, Gedeborg R. Anabolic steroids and cardiovascular risk: A national population-based cohort study. Drug and alcohol dependence. 2015 Jul 1:152():87-92. doi: 10.1016/j.drugalcdep.2015.04.013. Epub 2015 May 11
[PubMed PMID: 26005042]
[62]
Momin SB, Peterson A, Del Rosso JQ. A status report on drug-associated acne and acneiform eruptions. Journal of drugs in dermatology : JDD. 2010 Jun:9(6):627-36
[PubMed PMID: 20645524]
[63]
Heerfordt IM, Windfeld-Mathiasen J, Dalhoff KP, Mogensen M, Andersen JT, Horwitz H. Cutaneous manifestations of misuse of androgenic anabolic steroids: A retrospective cohort study. Journal of the American Academy of Dermatology. 2024 May:90(5):1047-1048. doi: 10.1016/j.jaad.2024.01.007. Epub 2024 Jan 10
[PubMed PMID: 38215797]
Level 2 (mid-level) evidence
[64]
van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BH. Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. International journal of sports medicine. 2003 Apr:24(3):195-6
[PubMed PMID: 12740738]
Level 3 (low-level) evidence
[65]
McGettigan MJ, Menias CO, Gao ZJ, Mellnick VM, Hara AK. Imaging of Drug-induced Complications in the Gastrointestinal System. Radiographics : a review publication of the Radiological Society of North America, Inc. 2016 Jan-Feb:36(1):71-87. doi: 10.1148/rg.2016150132. Epub
[PubMed PMID: 26761532]
[66]
Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Current sports medicine reports. 2006 Apr:5(2):104-9
[PubMed PMID: 16529682]
[67]
Ledesma BR, Weber A, Venigalla G, Muthigi A, Thomas J, Narasimman M, White J, Ramasamy R. Fertility outcomes in men with prior history of anabolic steroid use. Fertility and sterility. 2023 Dec:120(6):1203-1209. doi: 10.1016/j.fertnstert.2023.09.016. Epub 2023 Sep 26
[PubMed PMID: 37769866]
[68]
Chang S, Rasmussen JJ, Frandsen MN, Schou M, Johansen ML, Faber J, Münster AB, Sidelmann JJ, Kistorp C. Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers. Thrombosis and haemostasis. 2018 Apr:118(4):647-653. doi: 10.1055/s-0038-1636540. Epub 2018 Apr 4
[PubMed PMID: 29618151]
[69]
Ansell JE, Tiarks C, Fairchild VK. Coagulation abnormalities associated with the use of anabolic steroids. American heart journal. 1993 Feb:125(2 Pt 1):367-71
[PubMed PMID: 8427129]
[70]
Sidelmann JJ, Gram JB, Rasmussen JJ, Kistorp C. Anabolic-Androgenic Steroid Abuse Impairs Fibrin Clot Lysis. Seminars in thrombosis and hemostasis. 2021 Feb:47(1):11-17. doi: 10.1055/s-0040-1714398. Epub 2020 Oct 5
[PubMed PMID: 33017849]
[71]
Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2010 Oct:12(8):509-22. doi: 10.1111/j.1477-2574.2010.00222.x. Epub
[PubMed PMID: 20887318]
Level 1 (high-level) evidence
[72]
Gorayski P, Thompson CH, Subhash HS, Thomas AC. Hepatocellular carcinoma associated with recreational anabolic steroid use. British journal of sports medicine. 2008 Jan:42(1):74-5; discussion 75. doi: 10.1136/bjsm.2007.03932. Epub
[PubMed PMID: 18178686]
[73]
Woodward C, Smith J, Acreman D, Kumar N. Hepatocellular carcinoma in body builders; an emerging rare but serious complication of androgenic anabolic steroid use. Annals of hepato-biliary-pancreatic surgery. 2019 May:23(2):174-177. doi: 10.14701/ahbps.2019.23.2.174. Epub 2019 May 31
[PubMed PMID: 31225420]
[74]
Khalid S, Laput G, Khorfan K, Roytman M. Development of Liver Cancers as an Unexpected Consequence of Anabolic Androgenic Steroid Use. Cureus. 2023 Jan:15(1):e34357. doi: 10.7759/cureus.34357. Epub 2023 Jan 29
[PubMed PMID: 36874750]
[75]
Chegeni R, Pallesen S, McVeigh J, Sagoe D. Anabolic-androgenic steroid administration increases self-reported aggression in healthy males: a systematic review and meta-analysis of experimental studies. Psychopharmacology. 2021 Jul:238(7):1911-1922. doi: 10.1007/s00213-021-05818-7. Epub 2021 Mar 20
[PubMed PMID: 33745011]
Level 1 (high-level) evidence
[76]
Mustafa R, Hashmi HA. Drug-induced hirsutism. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2006 Jul:16(7):485-6
[PubMed PMID: 16827963]
[77]
Sharma A, Grant B, Islam H, Kapoor A, Pradeep A, Jayasena CN. Common symptoms associated with usage and cessation of anabolic androgenic steroids in men. Best practice & research. Clinical endocrinology & metabolism. 2022 Sep:36(5):101691. doi: 10.1016/j.beem.2022.101691. Epub 2022 Aug 12
[PubMed PMID: 35999138]
[78]
Albright JA, Lou M, Rebello E, Ge J, Testa EJ, Daniels AH, Arcand M. Testosterone replacement therapy is associated with increased odds of Achilles tendon injury and subsequent surgery: a matched retrospective analysis. Journal of foot and ankle research. 2023 Nov 11:16(1):76. doi: 10.1186/s13047-023-00678-0. Epub 2023 Nov 11
[PubMed PMID: 37950322]
Level 2 (mid-level) evidence
[79]
Sinha A, Deb VK, Datta A, Yadav S, Phulkar A, Adhikari S. Evaluation of structural features of anabolic-androgenic steroids: entanglement for organ-specific toxicity. Steroids. 2024 Dec:212():109518. doi: 10.1016/j.steroids.2024.109518. Epub 2024 Sep 24
[PubMed PMID: 39322097]
[80]
Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, Bhasin S. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men--a clinical research center study. The Journal of clinical endocrinology and metabolism. 1996 Oct:81(10):3754-8
[PubMed PMID: 8855834]
[81]
Börjesson A, Möller C, Hagelin A, Vicente V, Rane A, Lehtihet M, Dahl ML, Gårevik N, Ekström L. Male Anabolic Androgenic Steroid Users with Personality Disorders Report More Aggressive Feelings, Suicidal Thoughts, and Criminality. Medicina (Kaunas, Lithuania). 2020 May 28:56(6):. doi: 10.3390/medicina56060265. Epub 2020 May 28
[PubMed PMID: 32481676]
[82]
Karagun B, Altug S. Anabolic-androgenic steroids are linked to depression and anxiety in male bodybuilders: the hidden psychogenic side of anabolic androgenic steroids. Annals of medicine. 2024 Dec:56(1):2337717. doi: 10.1080/07853890.2024.2337717. Epub 2024 Apr 8
[PubMed PMID: 38590148]
[83]
Klonteig S, Scarth M, Bjørnebekk A. Sleep pathology and use of anabolic androgen steroids among male weightlifters in Norway. BMC psychiatry. 2024 Jan 22:24(1):62. doi: 10.1186/s12888-024-05516-6. Epub 2024 Jan 22
[PubMed PMID: 38254047]
[84]
Al-Hwiesh A, Al-Amoudi K, Alshehabi K, Abdelgalil M, Al-Hwiesh B, Alhwiesh A, Al-Audah N, Al Solami SM, Hamza WM, Abdul-Rahman IS. Coexistence of Interstitial Nephritis and the Cellular Variant of Focal Segmental Glomerulosclerosis Secondary to Anabolic Steroid Abuse. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2022 Nov 1:33(6):839-843. doi: 10.4103/1319-2442.390263. Epub 2023 Nov 29
[PubMed PMID: 38018725]
[85]
Shirpoor A, Naderi R. Nandrolone decanoate induced kidney injury through miRNA-146a targeting IRAK1 and TRAF6 via activation of the NF-κB pathway: The effect of moderate exercise. Steroids. 2024 Nov:211():109503. doi: 10.1016/j.steroids.2024.109503. Epub 2024 Aug 27
[PubMed PMID: 39208922]
[86]
Garner O, Iardino A, Ramirez A, Yakoby M. Cardiomyopathy induced by anabolic-androgenic steroid abuse. BMJ case reports. 2018 Jul 23:2018():. pii: bcr-2017-223891. doi: 10.1136/bcr-2017-223891. Epub 2018 Jul 23
[PubMed PMID: 30037963]
Level 3 (low-level) evidence
[87]
Costanzo PR, Pacenza NA, Aszpis SM, Suárez SM, Pragier UM, Usher JGS, Vásquez Cayoja M, Iturrieta S, Gottlieb SE, Rey RA, Knoblovits P. Clinical and Etiological Aspects of Gynecomastia in Adult Males: A Multicenter Study. BioMed research international. 2018:2018():8364824. doi: 10.1155/2018/8364824. Epub 2018 May 29
[PubMed PMID: 30003107]
Level 2 (mid-level) evidence
[88]
Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. The Journal of urology. 2018 Aug:200(2):423-432. doi: 10.1016/j.juro.2018.03.115. Epub 2018 Mar 28
[PubMed PMID: 29601923]
[89]
Gibbons SM, Moulding M, Bailey K, Stuart K, Wiffen S, Lewington AJ, Parker R, Lippiatt C, Guha N, O'Shea J, Owen M, Abbas A, Barth JH. Essential blood testing in the patient using androgenic anabolic steroids: a clinical practice guideline for primary care. The British journal of general practice : the journal of the Royal College of General Practitioners. 2024 Apr:74(741):187-190. doi: 10.3399/bjgp24X737013. Epub 2024 Mar 27
[PubMed PMID: 38538136]
Level 1 (high-level) evidence
[90]
Basaria S. Male hypogonadism. Lancet (London, England). 2014 Apr 5:383(9924):1250-63. doi: 10.1016/S0140-6736(13)61126-5. Epub 2013 Oct 10
[PubMed PMID: 24119423]
[91]
Moretti S, Lega F, Rigoni L, Saluti G, Giusepponi D, Gioiello A, Manuali E, Rossi R, Galarini R. Multiclass screening method to detect more than fifty banned substances in bovine bile and urine. Analytica chimica acta. 2018 Nov 22:1032():56-67. doi: 10.1016/j.aca.2018.06.037. Epub 2018 Jun 14
[PubMed PMID: 30143222]
[92]
Dahmani H, Louati K, Hajri A, Bahri S, Safta F. Development of an extraction method for anabolic androgenic steroids in dietary supplements and analysis by gas chromatography-mass spectrometry: Application for doping-control. Steroids. 2018 Oct:138():134-160. doi: 10.1016/j.steroids.2018.08.001. Epub 2018 Aug 15
[PubMed PMID: 30118779]
[93]
Smit DL, Bond P, de Ronde W. Health effects of androgen abuse: a review of the HAARLEM study. Current opinion in endocrinology, diabetes, and obesity. 2022 Dec 1:29(6):560-565. doi: 10.1097/MED.0000000000000759. Epub 2022 Aug 4
[PubMed PMID: 35938779]
Level 3 (low-level) evidence
[94]
Batrinos ML. Testosterone and aggressive behavior in man. International journal of endocrinology and metabolism. 2012 Summer:10(3):563-8. doi: 10.5812/ijem.3661. Epub 2012 Jun 30
[PubMed PMID: 23843821]
[95]
Rajmil O, Moreno-Sepulveda J. Recovery of spermatogenesis after androgenic anabolic steroids abuse in men. A systematic review of the literature. Actas urologicas espanolas. 2024 Mar:48(2):116-124. doi: 10.1016/j.acuroe.2023.07.007. Epub 2023 Aug 9
[PubMed PMID: 37567343]
Level 1 (high-level) evidence
[96]
McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian journal of andrology. 2016 May-Jun:18(3):373-80. doi: 10.4103/1008-682X.173938. Epub
[PubMed PMID: 26908067]
[97]
Esposito M, Salerno M, Calvano G, Agliozzo R, Ficarra V, Sessa F, Favilla V, Cimino S, Pomara C. Impact of anabolic androgenic steroids on male sexual and reproductive function: a systematic review. Panminerva medica. 2023 Mar:65(1):43-50. doi: 10.23736/S0031-0808.22.04677-8. Epub 2022 Feb 11
[PubMed PMID: 35146992]
Level 1 (high-level) evidence
[98]
de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU international. 2011 Dec:108(11):1860-5. doi: 10.1111/j.1464-410X.2011.10131.x. Epub 2011 Jun 17
[PubMed PMID: 21682835]
[99]
Campbell KJ. Anabolic steroid use and the uphill road to fertility recovery. Fertility and sterility. 2023 Dec:120(6):1173. doi: 10.1016/j.fertnstert.2023.10.012. Epub 2023 Oct 12
[PubMed PMID: 37838139]
[100]
Rasmussen JJ, Selmer C, Østergren PB, Pedersen KB, Schou M, Gustafsson F, Faber J, Juul A, Kistorp C. Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PloS one. 2016:11(8):e0161208. doi: 10.1371/journal.pone.0161208. Epub 2016 Aug 17
[PubMed PMID: 27532478]
Level 2 (mid-level) evidence
[101]
Frati P, Busardò FP, Cipolloni L, Dominicis ED, Fineschi V. Anabolic Androgenic Steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Current neuropharmacology. 2015 Jan:13(1):146-59. doi: 10.2174/1570159X13666141210225414. Epub
[PubMed PMID: 26074749]
[102]
Barbosa Neto O, da Mota GR, De Sordi CC, Resende EAMR, Resende LAPR, Vieira da Silva MA, Marocolo M, Côrtes RS, de Oliveira LF, Dias da Silva VJ. Long-term anabolic steroids in male bodybuilders induce cardiovascular structural and autonomic abnormalities. Clinical autonomic research : official journal of the Clinical Autonomic Research Society. 2018 Apr:28(2):231-244. doi: 10.1007/s10286-017-0470-2. Epub 2017 Oct 10
[PubMed PMID: 29019018]
[103]
Zhao H, Li JM, Li ZR, Zhang Q, Zhong MK, Yan MM, Qiu XY. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database. Frontiers in pharmacology. 2023:14():1182113. doi: 10.3389/fphar.2023.1182113. Epub 2023 Jul 12
[PubMed PMID: 37502210]
Level 2 (mid-level) evidence
[104]
Esposito M, Licciardello G, Privitera F, Iannuzzi S, Liberto A, Sessa F, Salerno M. Forensic Post-Mortem Investigation in AAS Abusers: Investigative Diagnostic Protocol. A Systematic Review. Diagnostics (Basel, Switzerland). 2021 Jul 21:11(8):. doi: 10.3390/diagnostics11081307. Epub 2021 Jul 21
[PubMed PMID: 34441242]
Level 1 (high-level) evidence
[106]
Dotka M, Małek ŁA. Myocardial Infarction in Young Athletes. Diagnostics (Basel, Switzerland). 2023 Jul 25:13(15):. doi: 10.3390/diagnostics13152473. Epub 2023 Jul 25
[PubMed PMID: 37568836]
[107]
Torrisi M, Pennisi G, Russo I, Amico F, Esposito M, Liberto A, Cocimano G, Salerno M, Li Rosi G, Di Nunno N, Montana A. Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review. Medicina (Kaunas, Lithuania). 2020 Nov 4:56(11):. doi: 10.3390/medicina56110587. Epub 2020 Nov 4
[PubMed PMID: 33158202]
[108]
Hernández-Guerra AI, Tapia J, Menéndez-Quintanal LM, Lucena JS. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic sciences research. 2019:4(3):267-273. doi: 10.1080/20961790.2019.1595350. Epub 2019 Aug 19
[PubMed PMID: 31489392]
Level 3 (low-level) evidence
[109]
Lichtenfeld J, Deal BJ, Crawford S. Sudden cardiac arrest following ventricular fibrillation attributed to anabolic steroid use in an adolescent. Cardiology in the young. 2016 Jun:26(5):996-8. doi: 10.1017/S104795111600007X. Epub 2016 Mar 16
[PubMed PMID: 26980272]
[110]
Karila D, Kerlan V, Christin-Maitre S. Androgenic steroid excess in women. Annales d'endocrinologie. 2024 Apr:85(2):142-149. doi: 10.1016/j.ando.2023.11.001. Epub 2023 Nov 29
[PubMed PMID: 38040089]
[111]
Havnes IA, Henriksen HCB, Johansen PW, Bjørnebekk A, Neupane SP, Hisdal J, Seljeflot I, Wisløff C, Jørstad ML, McVeigh J, Jørgensen AP. Off-label use of clomiphene citrate to treat anabolic androgenic steroid induced hypogonadism upon cessation among men (CloTASH) - A pilot study protocol. MethodsX. 2024 Dec:13():102810. doi: 10.1016/j.mex.2024.102810. Epub 2024 Jun 19
[PubMed PMID: 39022178]
Level 3 (low-level) evidence
[112]
Grant B, Campbell J, Pradeep A, Burns AD, Bassett P, Abbara A, Saket P, Minhas S, Dhillo WS, McVeigh J, Bhasin S, Jayasena CN. Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study. European journal of endocrinology. 2023 Dec 6:189(6):601-610. doi: 10.1093/ejendo/lvad164. Epub
[PubMed PMID: 38102386]
Level 2 (mid-level) evidence
[113]
Solanki P, Eu B, Smith J, Allan C, Lee K. Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocrine connections. 2023 Dec 1:12(12):. pii: e230358. doi: 10.1530/EC-23-0358. Epub 2023 Oct 19
[PubMed PMID: 37855241]
Level 2 (mid-level) evidence
[114]
Pope HG Jr, Kanayama G. Reduced Quality of Life in Former Androgen Users: An Evolving Public-Health Concern. The Journal of clinical endocrinology and metabolism. 2024 Apr 19:109(5):e1400-e1401. doi: 10.1210/clinem/dgad661. Epub
[PubMed PMID: 37955864]
Level 2 (mid-level) evidence
[115]
Bulut Y, Brandt-Jacobsen N, Buhl L, Schou M, Frystyk J, Kistorp C, Rasmussen JJ. Persistently Decreased Quality of Life and its Determinants in Previous Illicit Androgen Users. The Journal of clinical endocrinology and metabolism. 2024 Jan 18:109(2):e689-e697. doi: 10.1210/clinem/dgad551. Epub
[PubMed PMID: 37708363]
Level 2 (mid-level) evidence
[116]
Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, Bhasin S, Pope HG Jr. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. Addiction (Abingdon, England). 2015 May:110(5):823-31. doi: 10.1111/add.12850. Epub 2015 Feb 25
[PubMed PMID: 25598171]
[117]
Al Hashimi M. The deleterious effects of anabolic androgenic steroid abuse on sexual and reproductive health and comparison of recovery between treated and untreated patients: Single-center prospective randomized study. Andrologia. 2022 Dec:54(11):e14576. doi: 10.1111/and.14576. Epub 2022 Sep 5
[PubMed PMID: 36065528]
Level 1 (high-level) evidence
[118]
Vilar Neto JO, da Silva CA, Bruno da Silva CA, Pinto DV, Caminha JSR, de Matos RS, Nunes Filho JCC, Alves FR, Magalhães SC, De Francesco Daher E. Anabolic androgenic steroid-induced hypogonadism, a reversible condition in male individuals? A systematic review. Andrologia. 2021 Aug:53(7):e14062. doi: 10.1111/and.14062. Epub 2021 Apr 22
[PubMed PMID: 33887077]
Level 1 (high-level) evidence
[119]
Talih F, Fattal O, Malone D Jr. Anabolic steroid abuse: psychiatric and physical costs. Cleveland Clinic journal of medicine. 2007 May:74(5):341-4, 346, 349-52
[PubMed PMID: 17506239]
[120]
Kvillemo P, Gripenberg J, Strandberg AK, Elgán TH. Police officers' perspective on doping and prevention among recreational athletes: a cross-sectional study. Frontiers in sports and active living. 2023:5():1251531. doi: 10.3389/fspor.2023.1251531. Epub 2023 Oct 23
[PubMed PMID: 37936878]
Level 2 (mid-level) evidence
[121]
Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users' attitudes towards physicians. Addiction (Abingdon, England). 2004 Sep:99(9):1189-94
[PubMed PMID: 15317640]
[122]
Piatkowski T, De Andrade D, Neumann D, Tisdale C, Dunn M. Examining the association between trenbolone, psychological distress, and aggression among males who use anabolic-androgenic steroids. The International journal on drug policy. 2024 Dec:134():104636. doi: 10.1016/j.drugpo.2024.104636. Epub 2024 Oct 31
[PubMed PMID: 39486244]
[123]
Smit DL, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids: an overview. The Netherlands journal of medicine. 2018 May:76(4):167
[PubMed PMID: 29845939]
Level 3 (low-level) evidence
[124]
Creagh S, Warden D, Latif MA, Paydar A. The New Classes of Synthetic Illicit Drugs Can Significantly Harm the Brain: A Neuro Imaging Perspective with Full Review of MRI Findings. Clinical radiology & imaging journal. 2018:2(1):. pii: 000116. Epub 2018 Apr 25
[PubMed PMID: 30027157]
Level 3 (low-level) evidence
[125]
Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertility and sterility. 2014 May:101(5):1271-9. doi: 10.1016/j.fertnstert.2014.02.002. Epub 2014 Mar 14
[PubMed PMID: 24636400]
[126]
Andrews MA, Magee CD, Combest TM, Allard RJ, Douglas KM. Physical Effects of Anabolic-androgenic Steroids in Healthy Exercising Adults: A Systematic Review and Meta-analysis. Current sports medicine reports. 2018 Jul:17(7):232-241. doi: 10.1249/JSR.0000000000000500. Epub
[PubMed PMID: 29994823]
Level 1 (high-level) evidence
[127]
Elliott J, Kelly SE, Millar AC, Peterson J, Chen L, Johnston A, Kotb A, Skidmore B, Bai Z, Mamdani M, Wells GA. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ open. 2017 Nov 16:7(11):e015284. doi: 10.1136/bmjopen-2016-015284. Epub 2017 Nov 16
[PubMed PMID: 29150464]
Level 1 (high-level) evidence